epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-118, Phase II. In start-up

Treatment-resistant major depressive disorder

FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.

Where EPI-118 stands on September 30th 2026

  • Randomised0of 243 needed
  • Sites open0of 135 planned
  • Median forecast finishFeb 2029Deadline May 2029
  • FinishOn timeMedian forecast 3 months before the deadline.Open the plan
  • EnrolmentToo earlyToo few patients expected yet to judge.Open KPIs
  • SitesToo earlyNo site has been open long enough to judge.Open Sites
  • KRIs0 of 135 flaggedSites over at least one KRI threshold, each a candidate for a call, a targeted review or a visit.Open KRIs
  • QTLsToo earlyToo few patients yet to judge the study-level limits.Open QTLs

By country

EPI-118 by country
CountrySites openRandomisedBehindWaiting too long for a first patientOver a KRI threshold
United States0 of 600––0 of 60
United Kingdom0 of 250––0 of 25
Spain0 of 250––0 of 25
Poland0 of 250––0 of 25